Together, these data highlight a potential mechanistic basis for the observed enrichment of TIGIT+PD-1+ CD8+ T cells in CRC patients and provide a rationale for targeting these pathways therapeutically. This evidence concerns the gene PDCD1 and colorectal carcinoma.